Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PBMC15MCAR-NK
- Development stage
- Preclinical
- Lead developer
- University of California, Los Angeles
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intraperitoneal
01
Overview
PBMC15MCAR-NK is an experimental allogeneic cell therapy consisting of natural killer (NK) cells derived from peripheral blood mononuclear cells (PBMCs) and engineered to express a mesothelin-targeting chimeric antigen receptor (MCAR) and human interleukin-15 (IL-15). Developed as a comparator in preclinical studies for uterine endometrial carcinoma (UEC), these cells utilize the SS1 anti-mesothelin scFv for tumor recognition. The inclusion of IL-15 is intended to enhance the persistence and cytotoxic activity of the NK cells. While demonstrating potent short-term cytotoxicity against mesothelin-expressing tumor cells, PBMC15MCAR-NK cells showed limited expansion capacity and reduced long-term persistence compared to stem-cell-derived CAR-NKT platforms in serial tumor-killing models.
- Other names
- PBMC-derived IL-15-enhanced MCAR-engineered NK cellsPBMC-derived MCAR-IL15 NK cells
02
Targets
Mesothelin
Beyond the preview
Go deeper on PBMC15MCAR-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PBMC15MCAR-NK.